Home › Degenerasyon ng Macula › Tennessee
Pag-aaral pangklinika para sa Degenerasyon ng Macula sa Tennessee
7 pag-aaral para sa Degenerasyon ng Macula ang naghahanap ng mga kalahok sa mga site sa Tennessee.
Mga Lungsod sa Tennessee
Opisyal na teksto ng pag-aaral (English)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- Charles Retina Institute, Germantown
Nagre-recruitPhase 2/3
Edad 50 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07440225A Study in Adults With Geographic Atrophy
- Tennessee Retina, PC, Nashville
Nagre-recruitPhase 2
Edad 60 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07606365A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Tennessee Retina, PC, Nashville
- Vanderbilt Eye Institute, Nashville
Nagre-recruitPhase 3
Edad 50 hanggang 85 · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06541704Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Vanderbilt Eye Institute, Nashville
Nagre-recruitPhase 2
Edad 55 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT066594454D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- Tennessee Retina, Nashville
Nagre-recruitPhase 1/2
Edad 50 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT05197270A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- Southeastern Retina Associates, Hixson
- Southeastern Retina Associates (Site 095), Johnson City
- Southeastern Retina Associates, P.C., Knoxville
- at 1 pa
Nagre-recruitPhase 2/3
Edad 50 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07496567Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Tennessee Retina, PC, Nashville
Nagre-recruitPhase 3
Edad 50 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT07064759Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.